Trials / Completed
CompletedNCT06641037
A Study of LY3866288 in Healthy Participants
A Phase 1, Open-label, Randomized, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of LY3866288 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 19 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate how well LY3866288 is tolerated and what side effects may occur in healthy participants. The study drug will be administered orally. Blood tests will be performed to check how much LY3866288 gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 9 weeks including screening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3866288 | Administered orally |
Timeline
- Start date
- 2024-10-17
- Primary completion
- 2024-12-02
- Completion
- 2024-12-02
- First posted
- 2024-10-15
- Last updated
- 2025-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06641037. Inclusion in this directory is not an endorsement.